SCHEMBL15034646

SCHEMBL15034646

CC(C)(C)c1ccc(-c2nc(=O)o[nH]2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS O95271 4/20 0.47
TNKS2 Q9H2K2 4/20 0.47
PARP1 P09874 1/20 0.46
RARB P10826 1/20 0.46
NOTUM Q6P988 1/20 0.45
HDAC6 Q9UBN7 2/20 0.44
NPBWR1 P48145 1/20 0.42
KIF11 P52732 1/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
GABRA1 P14867 1/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
IKBKB O14920 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
HTT P42858 1/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
GCGR P47871 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15041027 0.80 TNKS2 (0.42) TNKSTNKS2PARP1NOTUMNPBWR1
SCHEMBL1437113 0.77 PARP1 (0.42) TNKSTNKS2PARP1NPBWR1NPC1
SCHEMBL15807126 0.76 NOTUM (0.45) NOTUMHDAC6NPBWR1NPC1RAB9A
SCHEMBL3743781 0.76 BTK (0.44) TNKSTNKS2PARP1NPC1RAB9A
SCHEMBL2440192 0.73
SCHEMBL7285207 0.72 KDM4E (0.47) PARP1NPC1RAB9AKDM4EALDH1A1
SCHEMBL18216833 0.69 RARB (0.83) TNKSTNKS2PARP1RARBNOTUM
SCHEMBL16644715 0.66 RAB9A (0.40) TNKSTNKS2PARP1NOTUMNPC1
SCHEMBL414390 0.66 HDAC6 (0.47) TNKSTNKS2PARP1RARBHDAC6
SCHEMBL9771856 0.66 BTK (0.51) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096527-B2 TRPM8 antagonists and their use in treatments AMGEN INC. (US) 2015-08-04 US disclosed
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20140235642-A1 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2014-08-21 US disclosed
US-8778941-B2 TRPM8 antagonists and their use in treatments AMGEN INC. (US) 2014-07-15 US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed
US-20130158034-A1 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2013-06-20 US disclosed
US-20130157996-A1 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158034-A1 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS TRPM8, TRPM7, TRPM5 TNKS 2754/4885TNKS2 2605/4885PARP1 4005/4885
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 TNKS 1833/4885TNKS2 2351/4885PARP1 3922/4885
US-20140235642-A1 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS TRPM8, TRPM7, TRPM5 TNKS 2754/4885TNKS2 2605/4885PARP1 4005/4885
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 TNKS 1833/4885TNKS2 2351/4885PARP1 3922/4885
US-20130157996-A1 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS TRPM8, TRPM7, TRPM5 TNKS 2754/4885TNKS2 2605/4885PARP1 4005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.